DIANA

Václav Navrátil, Jiří Schimer, Jan Tykvart, Tomáš Knedlík, Viktor Vik, Pavel Majer, Jan Konvalinka and Pavel Šácha

For a quick look click on the video
 

 
Challenge:

It has been shown that many proteins are functionally related to cancerogenesis. Reliable quantification of these proteins, so called biomarkers, in human serum or tissue biopsy samples represents a way to assess better diagnosis and improve patient outcome. Moreover, small molecule drugs inhibiting biological function of these proteins are also used in cancer therapy. Here we present a newly developed assay, called DIANA, which is capable of both selective protein detection and screening of small molecule inhibitors of those proteins.

Technology:

DIANA is a multiwell-plate based sandwich ELISA-like dual recognition assay, suitable for protein detection and screening of protein ligands that employs a fully synthetic detection probe. This probe is constructed from small molecule active site ligand and it consequently binds into the active site of the target protein.

Advantages of DIANA for protein detection: 

– Sensitivity: up to zeptomolar (10-21 M) amounts of target proteins are detected

– Selectivity: target proteins are selectively quantified in biological matrices (blood serum, urine, cell lysate)

– Broad linear range of up to six-logs

Advantages of DIANA for screening of small molecule ligands:

– Sensitivity: only small amounts (typically pictogram) of protein needed for screening

– Selectivity: no need for recombinant and/or purified proteins

– Dissociation constant can be determined from a single tested concentration

As we have shown on two proteins, DIANA has proven to be a excellent method for protein detection which is characterized by superior sensitivity, broad linear range and high selectivity. Additionally, it has two more unique advantages over most widely used sandwich immunoassays such as ELISA, immuno-PCR and proximity ligation/extension assay. Since the probe binds to the target at a defined site via small molecule ligand, the selectivity of binding of the probe can be always tested by titration with the free ligand. Moreover, in contrast to the sandwich immunoassays, this assay is not prone to false positive results due to interfering antibodies present in human blood and is therefore best suitable for use in in vitro diagnostics.

BioVaria 2016b

Figure . Dynamic range of quantification of PSMA (a) and CAIX (b) by DIANA

Commercial opportunity:

We have developed an ultrasensitive and selective ELISA-like assay for detection of target proteins in biological matrices with linear range of up to six logs. Moreover, the assay is suitable for accurate, quantitative and sensitive high-throughput screening of small molecule ligands on unpurified target proteins, most notably of competitive inhibitors of enzymes. Currently, we look for business partner who might be interested in collaborative commercial exploitation of the assay.

Development status:

The assay was developed to detect two relevant cancer associated proteins: Prostate Specific Membrane Antigen (PSMA) and carbonic anhydrase IX (CAIX). We were able to detect zeptomolar amounts of both enzymes, which translated into sensitivity of 1 pg/ml or lower in blood serum by analyzing 10 µl samples. We also showed the ability to quantitatively test competitive inhibitors of both enzymes, which was possible even when using untreated human serum as a source of the enzymes.

Patent situation:

CZE patent application filed 2014, PCT application filed 2015

Publications:

DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.

Navrátil V, Schimer J, Tykvart J, Knedlík T, Vik V, Majer P, Konvalinka J, Šácha P.

Nucleic Acids Res. 2016 Sep 26. full text version of the article can be find here.